79 related articles for article (PubMed ID: 9379441)
1. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
Jae HS; Winn M; Dixon DB; Marsh KC; Nguyen B; Opgenorth TJ; von Geldern TW
J Med Chem; 1997 Sep; 40(20):3217-27. PubMed ID: 9379441
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
Tasker AS; Sorensen BK; Jae HS; Winn M; von Geldern TW; Dixon DB; Chiou WJ; Dayton BD; Calzadila S; Hernandez L; Marsh KC; WuWong JR; Opgenorth TJ
J Med Chem; 1997 Jan; 40(3):322-30. PubMed ID: 9022798
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
von Geldern TW; Tasker AS; Sorensen BK; Winn M; Szczepankiewicz BG; Dixon DB; Chiou WJ; Wang L; Wessale JL; Adler A; Marsh KC; Nguyen B; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3668-78. PubMed ID: 10479298
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
[TBL] [Abstract][Full Text] [Related]
6. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Winn M; von Geldern TW; Opgenorth TJ; Jae HS; Tasker AS; Boyd SA; Kester JA; Mantei RA; Bal R; Sorensen BK; Wu-Wong JR; Chiou WJ; Dixon DB; Novosad EI; Hernandez L; Marsh KC
J Med Chem; 1996 Mar; 39(5):1039-48. PubMed ID: 8676339
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
9. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery.
Kitada K; Yui N; Matsumoto C; Mori T; Ohkita M; Matsumura Y
J Pharmacol Exp Ther; 2009 Dec; 331(3):998-1004. PubMed ID: 19737855
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
[TBL] [Abstract][Full Text] [Related]
12. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
13. Endothelin ETB receptor is involved in sex differences in the development of balloon injury-induced neointimal formation.
Kitada K; Yui N; Koyama M; Kimura K; Suzuki R; Tanaka R; Mori T; Ohkita M; Matsumura Y
J Pharmacol Exp Ther; 2011 Feb; 336(2):533-9. PubMed ID: 21075838
[TBL] [Abstract][Full Text] [Related]
14. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.
Bradbury RH; Bath C; Butlin RJ; Dennis M; Heys C; Hunt SJ; James R; Mortlock AA; Sumner NF; Tang EK; Telford B; Whiting E; Wilson C
J Med Chem; 1997 Mar; 40(6):996-1004. PubMed ID: 9083490
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists.
Wu C; Chan MF; Stavros F; Raju B; Okun I; Castillo RS
J Med Chem; 1997 May; 40(11):1682-9. PubMed ID: 9171877
[TBL] [Abstract][Full Text] [Related]
16. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?
Hay DW; Luttmann MA; Pullen MA; Nambi P
J Pharmacol Exp Ther; 1998 Feb; 284(2):669-77. PubMed ID: 9454813
[TBL] [Abstract][Full Text] [Related]
17. Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.
Cody WL; He JX; Reily MD; Haleen SJ; Walker DM; Reyner EL; Stewart BH; Doherty AM
J Med Chem; 1997 Jul; 40(14):2228-40. PubMed ID: 9216842
[TBL] [Abstract][Full Text] [Related]
18. Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
Amberg W; Hergenröder S; Hillen H; Jansen R; Kettschau G; Kling A; Klinge D; Raschack M; Riechers H; Unger L
J Med Chem; 1999 Aug; 42(16):3026-32. PubMed ID: 10447946
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
20. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.
Jae HS; Winn M; von Geldern TW; Sorensen BK; Chiou WJ; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 2001 Nov; 44(23):3978-84. PubMed ID: 11689084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
